STAT

After 9/11, we gave up privacy for security. Will we make the same trade-off after Covid-19?

The novel #coronavirus has upended the nation’s roiling health privacy debate, with Americans now being asked to accept surveillance of their movements, contacts, and health data.

In a span of weeks, the novel coronavirus has turned the nation’s roiling health privacy debate on its head. Concerns about what Google and Facebook might be doing with patients’ sensitive health information have receded, and instead, Americans are being asked to allow surveillance of their daily movements and contacts, and even their temperature and other physiological changes.

By tapping into people’s phones and medical records, researchers and public health authorities are hoping to more swiftly identify and isolate potentially infected patients and corral a pandemic that is outrunning them despite unprecedented restrictions on daily life.

Underscoring the urgency, the federal agency in charge of policing data breaches is now saying it will back off enforcement of certain privacy rules to make it easier for hospitals and their vendors to share patient medical records with public health officials. Meanwhile, the nation’s tech behemoths are collecting health information through Covid-19 symptom checkers, data that could prove invaluable to disease trackers when combined with travel and location data from smartphones.

“There are times that not using the information that we have is morally hard to defend, and I think this is one of them,” said Michelle Mello, a health law professor at Stanford University.

Read more: The U.S. gets a D-

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Plans For Generic Wegovy, Cough Syrup Warnings, And More
Biocon is developing a generic version of Novo Nordisk's Wegovy and is prepared to conduct a clinical trial next year if needed.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.

Related Books & Audiobooks